Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Proof-of-Concept, Multicentre, Open-Label, Randomised, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rezafungin Combined With 7 Days of Co-Trimoxazole Versus Co-Trimoxazole Monotherapy in HIV-Infected Adults With Pneumocystis Jirovecii Pneumonia

NCT05835479 is registered in ClinicalTrials.gov with Mundipharma Research Limited as lead sponsor.

NCT NCT05835479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Proof-of-Concept, Multicentre, Open-Label, Randomised, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rezafungin Combined With 7 Days of Co-Trimoxazole Versus Co-Trimoxazole Monotherapy in HIV-Infected Adults With Pneumocystis Jirovecii Pneumonia
Lead sponsor
Mundipharma Research Limited
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2023
Completion date
August 31, 2025
Enrollment
50 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pneumocystis pneumonia